Bayer EPS - Earnings per Share 2010-2024 | BAYRY

Bayer annual and quarterly earnings per share history from 2010 to 2024. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Bayer EPS for the quarter ending September 30, 2024 was $-1.17, a 7.65% decline year-over-year.
  • Bayer EPS for the twelve months ending September 30, 2024 was $-0.75, a 31.09% decline year-over-year.
  • Bayer 2023 annual EPS was $-0.81, a 172.75% decline from 2022.
  • Bayer 2022 annual EPS was $1.11, a 268.21% increase from 2021.
  • Bayer 2021 annual EPS was $0.3, a 109.9% decline from 2020.
Bayer Annual EPS
2023 $-0.81
2022 $1.11
2021 $0.30
2020 $-3.05
2019 $1.17
2018 $0.53
2017 $2.38
2016 $1.51
2015 $1.38
2014 $1.38
2013 $1.28
2012 $0.95
2011 $1.01
2010 $0.54
2009 $0.61
Bayer Quarterly EPS
2024-09-30 $-1.17
2024-06-30 $-0.52
2024-03-31 $0.55
2023-12-31 $0.39
2023-09-30 $-1.27
2023-06-30 $-0.52
2023-03-31 $0.60
2022-12-31 $0.11
2022-09-30 $0.14
2022-06-30 $-0.08
2022-03-31 $0.94
2021-12-31 $0.35
2021-09-30 $0.03
2021-06-30 $-0.72
2021-03-31 $0.64
2020-12-31 $0.02
2020-09-30 $-0.82
2020-06-30 $-2.68
2020-03-31 $0.42
2019-12-31 $0.43
2019-09-30 $0.26
2019-06-30 $0.12
2019-03-31 $0.36
2018-12-31 $-1.27
2018-09-30 $0.86
2018-06-30 $0.26
2018-03-31 $0.69
2017-12-31 $0.20
2017-09-30 $1.31
2017-06-30 $0.39
2017-03-31 $0.49
2016-12-31 $0.13
2016-09-30 $0.40
2016-06-30 $0.47
2016-03-31 $0.51
2015-12-31 $0.21
2015-09-30 $0.34
2015-06-30 $0.39
2015-03-31 $0.45
2014-12-31 $0.06
2014-09-30 $0.33
2014-06-30 $0.39
2014-03-31 $0.59
2013-12-31 $0.19
2013-09-30 $0.30
2013-06-30 $0.33
2013-03-31 $0.46
2012-12-31 $0.14
2012-09-30 $0.20
2012-06-30 $0.19
2012-03-31 $0.42
2011-12-31 $0.16
2011-09-30 $0.28
2011-06-30 $0.33
2011-03-31 $0.29
2010-12-31 $-0.08
2010-09-30 $0.11
2010-06-30 $0.20
2010-03-31 $0.28
2009-12-31 $0.07
2009-09-30 $0.11
2009-06-30 $0.23
2009-03-31 $0.18
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $21.338B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $688.937B 71.36
Johnson & Johnson (JNJ) United States $353.993B 14.36
Novo Nordisk (NVO) Denmark $353.124B 25.47
AbbVie (ABBV) United States $303.171B 15.96
Merck (MRK) United States $247.702B 16.46
Roche Holding AG (RHHBY) Switzerland $231.838B 0.00
AstraZeneca (AZN) United Kingdom $206.533B 17.57
Novartis AG (NVS) Switzerland $199.351B 13.25
Pfizer (PFE) United States $149.042B 10.19
Sanofi (SNY) $128.770B 11.66
Innoviva (INVA) United States $1.163B 9.68